Business
ICN Pharmaceuticals, which earlier this year made an unsuccessful run at Swiss drug giant F.
Nov. 3, 1988
W.H.
Dec. 27, 1997
Sales of two cholesterol drugs help the bottom line along with a recent downsizing campaign.
Jan. 30, 2007
Hepatitis: Schering-Plough says it can now sell ICN’s drug separate from interferon.
July 27, 2001
Pharmaceutical companies Merck & Co. and Schering-Plough Corp., partners in a lucrative cholesterol drug joint venture, posted hefty jumps in second-quarter profit Monday and beat analysts’ expectations.
July 24, 2007
Pharmaceuticals: Move could be prelude to acquisition of company that owns rights to the hepatitis C drug ribavirin.
Dec. 21, 2000
Regulation: Schering-Plough wants U.S. approval to sell combination to untreated patients.
June 17, 1998
Science & Medicine
A combination of drugs developed by Schering-Plough Corp. and Costa Mesa-based ICN Pharmaceuticals Inc. offers significant benefits in fighting hepatitis C in patients who haven’t ever been treated, new studies found.
May 19, 1998
Merck & Co., once a juggernaut among pharmaceutical companies, announced its first decline in quarterly earnings in nearly nine years Thursday, a day after Pfizer Inc. and Bristol-Myers Squibb Co. released disappointing forecasts for 2002.
April 19, 2002
Triton Biosciences Inc. said Friday that its pharmaceuticals business will be sold to Schering AG, a Berlin-based pharmaceuticals company with worldwide marketing that is trying to increase its presence in biotechnology.
Sept. 22, 1990